Omalizumab

Among patients with severe asthma receiving omalizumab, breathomics and plasma lipidomics predicted early and late treatment responses, according to results published in American Journal of Respiratory and Critical Care Medicine.

Biologics designed to counter type 2 inflammation reduced asthma exacerbations in real world settings, with dupilumab having the most impact, according to a study in he Journal of Allergy and Clinical Immunology: In Practice.

Immunotherapy, biologics, difficult cases, practice management and more are on the schedule of the seventh Food Allergy Support Team Annual Meeting, scheduled for Saturday and Sunday, June 21 and 22, in Dallas.

WASHINGTON — Physicians have a variety of safe and effective biologic choices for treating children with asthma, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Urticaria treatment guidelines in the United States include more options than the World Allergy Organization’s guidelines, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Children with severe allergic asthma and serum total IgE levels between 1,500 kU/L and 3,300 kU/L as well as food allergy benefitted from omalizumab, according to a study published in Pediatric Allergy and Immunology.

Robert Wood, MD, FAAAAI, professor of pediatrics Johns Hopkins University School of Medicine, recounted the results of the OUtMATCH study.

Patients with food allergy who used omalizumab experienced increased thresholds for reacting to peanut and other foods to which they were allergic, according to a study published in The New England Journal of Medicine.

The FDA approved omalizumab so people with immunoglobulin E-mediated food allergies can build tolerance to allergens, but experts warned that the biologic is not a cure.

Healio has compiled February’s most-read news in asthma and allergy.